Incyte Corp
Abierto
SectorSalud
104.06 -4.1
Resumen
Variación precio
24h
Mínimo
101.72
Máximo
108.51
Ingresos | 4.1M 303M |
|---|---|
Ventas | -234M 1.3B |
P/B Media del Sector | 14.215 49.052 |
BPA | 1.81 |
Margen de beneficio | 23.834 |
Empleados | 2,844 |
EBITDA | -47M 368M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 meses | +1.7% upside |
Próximas Ganancias | 28 jul 2026 |
|---|
Capitalización de Mercado | 1.1B 20B |
|---|---|
Apertura anterior | 108.16 |
Cierre anterior | 104.06 |
Noticias sobre sentimiento de mercado
By Acuity
16%
84%
22 / 342 Clasificación en Healthcare
Incyte Corp Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Acerca de Incyte Corp
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation